List of investigational analgesics

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

This is a list of investigational analgesics, or analgesics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.

Opioid receptor modulators[edit]

Sodium channel blockers[edit]

TRP channel modulators[edit]

Cannabinoid receptor modulators[edit]

Nerve growth factor inhibitors[edit]

Others[edit]

See also[edit]

References[edit]

  1. ^ Zhu L, et al. Novel Opioid-Receptor Agonists with Reduced Morphine-like Side Effects. Mini Rev Med Chem. 2018 Jul 16. Zhu, Lianghan; Cui, Zhiying; Zhu, Qihua; Zha, Xiaoming; Xu, Yungen (2018). "Novel Opioid Receptor Agonists with Reduced Morphine-like Side Effects". Mini-Reviews in Medicinal Chemistry. 18 (19): 1603–1610. doi:10.2174/1389557518666180716124336. PMID 30009707.
  2. ^ Zaccara G, Schmidt D (2017). "Antiepileptic Drugs in Clinical Development: Differentiate or Die?". Curr. Pharm. Des. 23 (37): 5593–5605. doi:10.2174/1381612823666170809100524. PMID 28799516.
  3. ^ Nakamura, M., Shin, H., & Jang, I. S. (2018). Mechanism of Action of Cenobamate: Preferential Inhibition of the Persistent Sodium Current (P5. 278). http://n.neurology.org/content/90/15_Supplement/P5.278
  4. ^ Manitpisitkul, Prasarn; Shalayda, Kevin; Russell, Lucille; Sanga, Panna; Solanki, Bhavna; Caruso, Joseph; Iwaki, Yuki; Moyer, John A. (2018). "Pharmacokinetics and Safety of Mavatrep (JNJ-39439335), a TRPV1 Antagonist in Healthy Japanese and Caucasian Men: A Double-Blind, Randomized, Placebo-Controlled, Sequential-Group Phase 1 Study". Clinical Pharmacology in Drug Development. 7 (7): 712–726. doi:10.1002/cpdd.413. ISSN 2160-7648. PMID 29125703. S2CID 11755963.
  5. ^ Manitpisitkul, Prasarn; Shalayda, Kevin; Russell, Lucille; Sanga, Panna; Williams, Yinka; Solanki, Bhavna; Caruso, Joseph; Moyer, John A. (2018). "Bioavailability and Pharmacokinetics of TRPV1 Antagonist Mavatrep (JNJ-39439335) Tablet and Capsule Formulations in Healthy Men: Two Open-Label, Crossover, Single-Dose Phase 1 Studies". Clinical Pharmacology in Drug Development. 7 (7): 699–711. doi:10.1002/cpdd.412. ISSN 2160-7648. PMID 29125700. S2CID 32666782.

External links[edit]